AGER and cancer: Extracellular S100A8/A9 released by cancer cells interacts with surface receptors including Toll-like receptor 4 (TLR4) and RAGE (Receptor for Advanced Glycation End products) (13, 14), thereby promoting directed chemotaxis of myeloid cells and inducing proinflammatory responses and/or immune suppression by activation of JAK-STAT, NF-κB, and MAPK pathways (12, 15, 16).